Akt isoform-specific effects on thyroid cancer development and progression in a murine thyroid cancer model
暂无分享,去创建一个
K. Coombes | K. L. La Perle | P. Tsichlis | Caroline Kim | M. Saji | Sheue-yann Cheng | M. Ringel | Xiaoli Zhang | Tilak Khanal | Chaojie Wang | S. Cheng | Xiaoli Zhang
[1] G. Pidgeon,et al. The next generation of PI3K-Akt-mTOR pathway inhibitors in breast cancer cohorts. , 2018, Biochimica et biophysica acta. Reviews on cancer.
[2] Michael C. Ostrowski,et al. Stromal PTEN determines mammary epithelial response to radiotherapy , 2018, Nature Communications.
[3] G. Mills,et al. AKT isoform-specific expression and activation across cancer lineages , 2018, BMC cancer.
[4] F. Meric-Bernstam,et al. Targeting the PI3K pathway in cancer: are we making headway? , 2018, Nature Reviews Clinical Oncology.
[5] J. Greenman,et al. The Role of Chemokines in Thyroid Carcinoma. , 2017, Thyroid : official journal of the American Thyroid Association.
[6] R. Vishwakarma,et al. Protein kinase B: emerging mechanisms of isoform-specific regulation of cellular signaling in cancer. , 2017, Anti-cancer drugs.
[7] D. Bar-Sagi,et al. Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer , 2017, Cell reports.
[8] R. Lloyd,et al. The evolving concept of cancer stem-like cells in thyroid cancer and other solid tumors , 2017, Laboratory Investigation.
[9] D. Gabrilovich,et al. Dendritic cells in cancer: the role revisited. , 2017, Current opinion in immunology.
[10] Lianbo Yu,et al. RCAN1-4 is a thyroid cancer growth and metastasis suppressor. , 2017, JCI insight.
[11] P. Soares,et al. Molecular Markers Involved in Tumorigenesis of Thyroid Carcinoma: Focus on Aggressive Histotypes , 2017, Cytogenetic and Genome Research.
[12] J. Fagin,et al. Biologic and Clinical Perspectives on Thyroid Cancer. , 2016, The New England journal of medicine.
[13] G. Marone,et al. The immune network in thyroid cancer , 2016, Oncoimmunology.
[14] Amruta Ashtekar,et al. Mouse models of thyroid cancer: A 2015 update , 2016, Molecular and Cellular Endocrinology.
[15] A. Hague,et al. The PI3K/Akt Pathway in Tumors of Endocrine Tissues , 2016, Front. Endocrinol..
[16] A. Palmer,et al. Analysis of exosome release as a cellular response to MAPK pathway inhibition. , 2015, Langmuir : the ACS journal of surfaces and colloids.
[17] W. Faquin,et al. Tumor-Associated Inflammatory Cells in Thyroid Carcinomas. , 2014, Surgical pathology clinics.
[18] R. Saunders,et al. A Tale of Mice and Men: The WPA, the LSU Indian Room Museum, and the Emergence of Professional Archaeology in the U.S. South , 2014 .
[19] A. Toker,et al. Signaling specificity in the Akt pathway in biology and disease. , 2014, Advances in biological regulation.
[20] J. Petrik,et al. Opposing Functions of Akt Isoforms in Lung Tumor Initiation and Progression , 2014, PloS one.
[21] Andrew H. Beck,et al. Targeting Akt3 signaling in triple-negative breast cancer. , 2014, Cancer research.
[22] J. Garcia-Vallejo,et al. The physiological role of DC-SIGN: a tale of mice and men. , 2013, Trends in immunology.
[23] K. Flaherty,et al. BRAF in Melanoma: Current Strategies and Future Directions , 2013, Clinical Cancer Research.
[24] J. Casal,et al. Akt2 interacts with Snail1 in the E-cadherin promoter , 2012, Oncogene.
[25] G. Kerr,et al. Proximity ligation assays for isoform‐specific Akt activation in breast cancer identify activated Akt1 as a driver of progression , 2012, The Journal of pathology.
[26] Qiaojia Huang,et al. Akt2 Kinase Suppresses Glyceraldehyde-3-phosphate Dehydrogenase (GAPDH)-mediated Apoptosis in Ovarian Cancer Cells via Phosphorylating GAPDH at Threonine 237 and Decreasing Its Nuclear Translocation* , 2011, The Journal of Biological Chemistry.
[27] Sydney L. Stoops,et al. Inhibition of Akt with small molecules and biologics: historical perspective and current status of the patent landscape , 2011, Expert opinion on therapeutic patents.
[28] N. Hay,et al. The effect Akt2 deletion on tumor development in Pten+/− mice , 2011, Oncogene.
[29] A. Fusco,et al. Group I p21-activated kinases regulate thyroid cancer cell migration and are overexpressed and activated in thyroid cancer invasion. , 2010, Endocrine-related cancer.
[30] R. Steinman,et al. Microbial Stimulation Fully Differentiates Monocytes to DC-SIGN/CD209+ Dendritic Cells for Immune T Cell Areas , 2010, Cell.
[31] R. Figlin,et al. Akt inhibitors in clinical development for the treatment of cancer , 2010, Expert opinion on investigational drugs.
[32] W. Muller,et al. Distinct biological roles for the akt family in mammary tumor progression. , 2010, Cancer research.
[33] M. Willingham,et al. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma. , 2010, Endocrinology.
[34] T. McGraw,et al. The Akt kinases: Isoform specificity in metabolism and cancer , 2009, Cell cycle.
[35] G. Mills,et al. Akt1 and akt2 play distinct roles in the initiation and metastatic phases of mammary tumor progression. , 2009, Cancer research.
[36] Harold Varmus,et al. Seeding and Propagation of Untransformed Mouse Mammary Cells in the Lung , 2008, Science.
[37] M. Carrington,et al. The evolutionary history of the CD209 (DC-SIGN) family in humans and non-human primates , 2008, Genes and Immunity.
[38] Ken Jacobson,et al. Distribution and lateral mobility of DC-SIGN on immature dendritic cells–implications for pathogen uptake , 2008, Journal of Cell Science.
[39] Lewis C. Cantley,et al. AKT/PKB Signaling: Navigating Downstream , 2007, Cell.
[40] M. Saji,et al. AKT in thyroid tumorigenesis and progression. , 2007, Endocrinology.
[41] Huiling He,et al. Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion , 2007, Proceedings of the National Academy of Sciences.
[42] M. Saji,et al. Molecular mechanisms involved in differentiated thyroid cancer invasion and metastasis , 2007, Current opinion in oncology.
[43] K. Slawin,et al. An essential role for Akt1 in dendritic cell function and tumor immunotherapy , 2006, Nature Biotechnology.
[44] Brian A. Hemmings,et al. Only Akt1 Is Required for Proliferation, while Akt2 Promotes Cell Cycle Exit through p21 Binding , 2006, Molecular and Cellular Biology.
[45] Li Hao,et al. DC-SIGN and immunoregulation. , 2006, Cellular & molecular immunology.
[46] Hong Liu,et al. Mechanism of Akt1 inhibition of breast cancer cell invasion reveals a protumorigenic role for TSC2. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[47] Sheue-yann Cheng,et al. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[48] J. Brugge,et al. Distinct roles of Akt1 and Akt2 in regulating cell migration and epithelial–mesenchymal transition , 2005, The Journal of cell biology.
[49] Caroline Kim,et al. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma. , 2005, Endocrinology.
[50] J. Frahm,et al. Essential role of protein kinase Bγ (PKBγ/Akt3) in postnatal brain development but not in glucose homeostasis , 2005, Development.
[51] V. Vasko,et al. Akt1 contains a functional leucine-rich nuclear export sequence. , 2005, Biochemical and biophysical research communications.
[52] T. Ludwig,et al. Role for Akt3/Protein Kinase Bγ in Attainment of Normal Brain Size , 2005, Molecular and Cellular Biology.
[53] Robert D Cardiff,et al. Activation of Akt-1 (PKB-alpha) can accelerate ErbB-2-mediated mammary tumorigenesis but suppresses tumor invasion. , 2004, Cancer research.
[54] V. Vasko,et al. Akt activation and localisation correlate with tumour invasion and oncogene expression in thyroid cancer , 2004, Journal of Medical Genetics.
[55] J. Stock,et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. , 2003, The Journal of clinical investigation.
[56] M. Willingham,et al. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis. , 2002, Thyroid : official journal of the American Thyroid Association.
[57] R. Doms,et al. Expression of DC-SIGN by Dendritic Cells of Intestinal and Genital Mucosae in Humans and Rhesus Macaques , 2002, Journal of Virology.
[58] M. Willingham,et al. A targeted dominant negative mutation of the thyroid hormone α1 receptor causes increased mortality, infertility, and dwarfism in mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[59] M. Birnbaum,et al. Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.
[60] I. Roninson,et al. Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. , 2001, Genes & development.
[61] M. Saji,et al. Overexpression and overactivation of Akt in thyroid carcinoma. , 2001, Cancer research.
[62] K. Kaestner,et al. Insulin Resistance and a Diabetes Mellitus-Like Syndrome in Mice Lacking the Protein Kinase Akt2 (PKBβ) , 2001 .
[63] M. Saji,et al. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. , 2001, Thyroid : official journal of the American Thyroid Association.
[64] P. Pandolfi,et al. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse , 2001, Nature Genetics.
[65] M. Willingham,et al. Mice with a targeted mutation in the thyroid hormone beta receptor gene exhibit impaired growth and resistance to thyroid hormone. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[66] J. Dumont,et al. Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. , 2000, The Biochemical journal.
[67] D. Jarjoura,et al. Akt deficiency delays tumor progression , vascular invasion , and distant metastases in a murine model of thyroid cancer , 2011 .
[68] S. Naber,et al. Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. , 2007, Cancer research.
[69] Ximing J. Yang,et al. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. , 2006, Genes & development.
[70] T. Ludwig,et al. Role for Akt3/protein kinase Bgamma in attainment of normal brain size. , 2005, Molecular and cellular biology.
[71] H. Seo,et al. Thyroid hormone induces rapid activation of Akt/protein kinase B-mammalian target of rapamycin-p70S6K cascade through phosphatidylinositol 3-kinase in human fibroblasts. , 2005, Molecular endocrinology.
[72] K. Kaestner,et al. Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). , 2001, Science.
[73] [Carcinoma]. , 1955, Die Medizinische.